|
Study Name |
Drug name or type |
Disease |
PI |
Contact |
|
AstraZeneca D5164C00001 (ADAURA) NSCLC |
osimertinib (3rd generation EGFR TKI) versus placebo |
EGFR mutation positive, stage IB-IIIA NSCLC, following complete tumor resection |
Goldman |
Jaime Hunt (310) 794-3894 |
|
Lilly 14T-MC-JVCY NSCLC |
ramucirumab (anti-VEGFR2) versus placebo |
treatment naïve, EGFR mutation positive, NSCLC |
Garon |
Jaime Hunt (310) 794-3896 |
|
MedImmune D4190C00006 NSCLC |
MEDI4736 (anti-PD-L1) + tremelimumab (anti-CTLA-4) |
previously treated, NSCLC |
Garon |
Jaime Hunt (310) 794-3897 |
|
Plexxikon PLX108-14 Solid Tumors |
PLX3397 (CSF1R inhibitor) + pembrolizumab (immunotherapy) |
Solid Tumors |
Hu-Lieskovan |
Jaime Hunt (310) 794-3898 |
|
MacroGenics CP-MGA271-02 Solid Tumors |
MGA271 + Ipilimumab (anti-CTLA-4) |
Chimielowski |
Jaime Hunt (310) 794-3899 |
|
|
Abound 70+ |
abraxane + carboplatin |
elderly subjects + advanced NSCLC |
Goldman |
Jaime Hunt (310) 794-3900 |
|
Amgen 20070782 |
Chemotherapy |
Anemic NSCLC |
Glaspy |
Jaime Hunt (310) 794-3901 |
|
Celgene ABI-007-ST-001 Solid Tumors |
Azacitidine + chemotherapy |
Solid Tumors |
Wainberg |
Jaime Hunt (310) 794-3902 |
|
Checkmate 153 |
Nivolumab (anti-PD-1) |
previously treated, adanced or metastatic NSCLC |
Garon |
Jaime Hunt (310) 794-3903 |
|
EMD Serono EMR100070-001 Solid Tumor |
Avelumab (anti-PD-L1) |
Solid Tumors |
Wong |
Jaime Hunt (310) 794-3904 |
|
Lilly 13Y-MC-JPBJ NSCLC |
LY2835219 + anti cancer drug (pemetrexed, gemcitabine, ramucirumab, LY3023414) |
Stage IV NSCLC |
Goldman |
Jaime Hunt (310) 794-3905 |
|
Lilly I3Y-MC-JPBK |
Abemaciclib (CDK 4/6 Dual Inhibitor) + SOC vs. Erlotinib + SOC |
Previously treated KRASm metastatic NSCLC |
Goldman |
Jaime Hunt (310) 794-3906 |
|
Pfizer B1641003 Solid Tumors |
Pf-05082566 (4-1bb agonist) + pembrolizumab (anti-PD-L1) |
Previously treated advanced/metastatic solid tumors |
Hu-Lieskovan |
Jaime Hunt (310) 794-3907 |
|
Pfizer B2151002 Solid Tumors |
PF-05212384 (PI3K/MTOR inhibitor) + docetaxel, cisplatin, or dacomitinib |
NSCLC |
Wainberg |
Jaime Hunt (310) 794-3908 |
|
Roche GO29322 Solid Tumors |
MPDL3280A (anti-PD-L1) + Ipilimumab (anti-CTLA-4) vs MPDL3280A + Interferon-alpha |
Advanced or metastatic solid tumors |
Wong |
Jaime Hunt (310) 794-3909 |
|
Pfizer B1641001 Advanced Cancer/NHL |
PF-05082566 (anti 4-1BB) |
relapsed or refractory NSCLC |
Hu-Lieskovan |
Jaime Hunt (310) 794-3911 |
|
BI 1302.5 |
BI 695502 (angiogenesis inhibitor) plus chemotherapy versus Avastin (angiogenesis inhibitor) plus chemotherapy |
advanced, nonsquamous, NSCLC |
Garon |
Jaime Hunt (310) 794-3912 |
|
Checkmate 370 |
Nivolumab (immunotherapy) |
treatment naïve or previously treated with chemotherapy, advanced NSCLC |
Glaspy |
Jaime Hunt (310) 794-3913 |
|
CINC280A2201 |
INC280 (cMET Inhibitor) |
NSCLC who have received one or two prior lines of systemic therapy |
Garon |
Jaime Hunt (310) 794-3914 |
